M. Joshi

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E

M. Bhasin, C. Nucera, S. Karumanchi, 2017, Oncotarget.

Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts

M. Bhasin, P. Catalano, S. Alper, 2019, Oncogenesis.

Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

M. Galsky, J. Riess, M. Robson, 2023, medRxiv.

Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses

P. Neven, H. Rugo, Yeon-Hee Park, 2022, Cancer Research.